Targeting the Tie2/Tek Receptor in Astrocytomas

American Journal of Pathology

Volumn 164, Issue 2, 2004, Pages 467-476

  Zadeh, Gelareh ^a   Qian, Baoping ^a   Okhowat, Ali ^a   Sabha, Nesrin ^a   Kontos, Christopher D ^c   Guha, Abhijit ^a,b,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; PROTEIN TYROSINE KINASE; TEK RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CELL SPECIFICITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME DEFICIENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR VASCULARIZATION; VASCULARIZATION; XENOGRAFT; ANIMAL; CANCER INVASION; CELL STRAIN 3T3; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2;

EID: 1542319875     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63137-9     Document Type: Article

References (52)

1. Folkman J, Klein G, Weinhouse S (Eds): Tumor angiogenesis. Advances in Cancer Research. New York, Academic Press, 1974, pp 43-52
2. Folkman J: Angiogenesis-dependent diseases. Semin Oncol 2001, 28:536-542
3. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257
4. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248
5. Breier G, Albrecht U, Sterrer S, Risau W: Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992, 114:521-532
6. Ferrara N: VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000, 11:617-624
7. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803
8. Machein MR, Plate KH: VEGF in brain tumors. J Neurooncol 2000, 50:109-120
9. Patan S: Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000, 50:1-15
10. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994, 59:520-529
11. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169
12. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998
13. Holash J, Wiegand SJ, Yancopoulos GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999, 18: 5356-5362
14. Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R, Breitman ML: The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 1993, 8:1293-1301
15. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60
16. Hanahan D: Signalling vascular morphogenesis and maintenance. Science 1997, 277:48-50
17. Jones N, Dumont DJ: The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene 1998, 17:1097-1108
18. Jones N, Dumont DJ: Tek/Tie2 signaling: new and old partners. Cancer Metastasis Rev 2000, 19:13-17
19. Jones N, Voskas D, Master Z, Sarao R, Jones J, Dumont DJ: Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function. EMBO Rep 2001, 2:438-445
20. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC: Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999, 79:213-223
21. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY: Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 2000, 86:24-29
22. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 2000, 19:4549-4552
23. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO: Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001, 276:26516-26525
24. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD: Increased vascularization in mice overexpressing angiopoietin-1. Science 1998, 282:468-471
25. Thurston G: Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat 2002, 200:575-580
26. Visconti RP, Richardson CD, Sato TN: Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 2002, 99:8219-8224
27. Ward NL, Dumont DJ: The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development. Semin Cell Dev Biol 2002, 13:19-27
28. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002, 3:411-423
29. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998, 95:8829-8834
30. Zadeh G, Guha A: Neoangiogenesis in human astrocytomas: expression and functional role of angiopoietins and their cognate receptors. Front Biosci 2003, 8:E128-E137
31. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, Stewart DJ: Article SDL-eP-J: biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001, 49:659-670
32. Ding H, Roncari L, Wu X, Lau N, Shannon P, Nagy A, Guha A: Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro-oncology 2001, 3:1-10
33. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF: An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000, 92:326-333
34. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103: 159-165
35. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K: Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997, 100:2072-2078
36. Burger PC, Scheithauer BW: Tumors of the central nervous system. Atlas of the Tumor Pathology. Washington, DC, Armed Forces Institute of Pathology, 1994
37. Kleihues P, Cavenee W: Tumors of the Nervous System. Washington, DC, IARC Press, 2000, pp 52-56
38. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997, 32:253-265
39. Brat DJ, Van Meir EG: Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol 2001, 158:789-796
40. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, Ploplis V, Muller M, Nagy A, Plow E, Gerard R, Edgington T, Risau W, Collen D: Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann NY Acad Sci 1997, 811:191-206
41. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844
42. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998, 9:49-58
43. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367:576-579
44. Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH: Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int J Cancer 2001, 91:273-282
45. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, Grumet M: In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999, 159:391-400
46. Stratmann A, Risau W, Plate KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998, 153:1459-1466
47. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, Ushio Y: Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001, 61: 6248-6254
48. Audero E, Cascone I, Zanon I, Previtali SC, Piva R, Schiffer D, Bussolino F: Expression of angiopoietin-1 in human glioblastomas regulates tumor-induced angiogenesis: in vivo and in vitro studies. Arterioscler Thromb Vasc Biol 2001, 21:536-541
49. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, Martiny-Baron G: Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999, 59:3185-3191
50. Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, Shaheen RM, Bucana CD, Ellis LM: The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001, 61:1255-1259
51. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, Riccardi L, Lange-Asschenfeldt B, Detmar M: Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002, 160: 1381-1392
52. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY: Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999, 448:249-253